OA 02.01 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma
Hedy L. Kindler1, Silvia Novello2, Dean A. Fennell3, George R. Blumenschein4, Alessandra Bearz5, Giovanni Luca Ceresoli6, Joachim Aerts7, James Spicer8, Paul Taylor9, Alastair Greystoke10, Kristiaan Nackaerts11, Luana Calabrò12, Sjaak A. Burgers13, Ross Jennens14, Andrea Sporchia15, Annette O. Walter16, Jonathan Siegel17, Barrett H. Childs17, Cem Elbi17, Raffit Hassan18
1Section of Hematology/Oncology, University of Chicago, Chicago, IL/US
2University of Turin, Department of Oncology, S. Luigi Hospital, Torino/IT
3Cancer Research Uk Center, University of Leicester & Leicester University Hospitals, Leicester/GB
4University of Texas, MD Anderson Cancer Center, Houston, TX, US
5Medical Oncology, CRO-IRCCS, Aviano/IT
6Oncology, Cliniche Humanitas Gavazzeni, Bergamo/IT
7Pulmonary Diseases, Erasmus MC Cancer Center, Rotterdam/NL
8Guy’s & St. Thomas’ NHS Trust; King’S College London, London/GB
9University Hospitals of South Manchester, Manchester/GB
10Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne/GB
11KU Leuven, University Hospitals, Leuven/BE
12Medical Oncology and Immunotherapy, University Hospital of Siena, Siena/IT
13Netherlands Cancer Institute, Amsterdam, NL
14Epworth Healthcare, Richmond/AU
15Bayer, Italy, Milan/IT
16Bayer AG, Berlin/DE
17Bayer Healthcare Pharmaceuticals Inc, Whippany/US
18Thoracic and Gi Oncology Branch, National Cancer Institute, Bethesda/US
Tóm tắt
Từ khóa
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
Journal of Thoracic Oncology
Tập 12 Số 11
S1746
Thông tin tác giả